Original from: businesswire
QIAGEN N.V. announced it has entered into a strategic partnership with Servier, a global pharmaceutical group, to develop a companion diagnostic test for TIBSOVO®, an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of the blood cancer acute myeloid leukemia (AML).
Under the Master Collaboration Agreement, QIAGEN will develop and validate a real-time in vitro PCR test that can be used to detect IDH1 gene mutations in AML patients in whole blood and bone marrow aspirates.
The companion diagnostic will run on the QIAGEN Rotor-Gene Q MDx device, which is widely used by labs worldwide. QIAGEN¡¯s experienced regulatory teams will support clinical validation of the companion diagnostic and its approval in the US, the European Union and Japan.
¡°Patients with AML may deteriorate rapidly if not treated quickly so we are pleased to support Servier with a companion diagnostic in their mission to propose innovative treatment for IDH1 mutated AML patients,¡± said Jonathan Arnold, Vice President, Head of Partnering for Precision Diagnostics, at QIAGEN. ¡°At the same time, we are further strengthening our role in developing companion diagnostics for the ever-growing number of biomarkers being discovered in onco-hematology.¡±
Brian Lockhart, Global Head of Companion Diagnostics at Servier, said: ¡°In order to expand the global access for TIBSOVO® for patients, it is imperative that we leverage a partner such as QIAGEN with an established global footprint in oncology-driven diagnostics, and a proven expertise in companion diagnostics development and approvals.¡±
AML is a hard-to-treat cancer of the blood and bone marrow. IDH1 mutations are present in about 6 to 10 percent of cases1. One of the most common types of leukemia in adults, the disease often occurs in patients in their late 60s or older.
QIAGEN is a pioneer in precision medicine and the leader in collaborating with pharmaceutical and biotechnology companies to develop companion diagnostics. These can detect genetic abnormalities to provide insights that guide clinical decision-making about treatments. From polymerase chain reaction (PCR) and digital PCR (dPCR) to next-generation sequencing (NGS), QIAGEN offers an unmatched breadth of technologies, which means it can tailor products to partners¡¯ needs.
QIAGEN has master collaboration agreements to develop and commercialize companion diagnostics with more than 30 global companies ¨C a deep pipeline that will advance so-called precision medicine, which tailors a patient¡¯s treatment to the genetic profile identified by companion diagnostics testing. QIAGEN currently has eleven PCR-based companion-diagnostics tests that have been approved by the US Food and Drug Administration (FDA). Furthermore, the company announced collaborations with Neuron23 and Helix to develop companion diagnostics in disease areas outside oncology.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies) and Academia (life sciences research). As of September 30, 2022, QIAGEN employed more than 6,200 people in over 35 locations worldwide.
